ESCAPE BIO
Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule drugs intended to treat neurodegenerative diseases. The company is developing therapeutics for the novel, precisely therapies for genetic neurodegenerative diseases. Escape Bio's pipeline includes candidates targeting known genetic drivers of multiple diseases, including ESB1609, a small molecule S1P5 receptor agonist for the treatment of CNS lysosomal storage disorders and ESB5070, a small molecule kinase inhibitor for Parkinsonโs disease patients who have an LRRK2 G2019S variant and an Alzheimer's disease program targeting ApoE4. E-scape Bio was founded in 2015 and is headquartered in San Francisco, California, United States.
ESCAPE BIO
Social Links:
Industry:
Biotechnology Health Care Medical
Founded:
2015-01-01
Address:
South San Francisco, California, United States
Country:
United States
Website Url:
http://www.escapebio.com
Total Employee:
11+
Status:
Active
Contact:
650-431-0100
Email Addresses:
[email protected]
Total Funding:
187.08 M USD
Technology used in webpage:
SPF Microsoft Exchange Online Amazon Office 365 Mail GoDaddy DNS AWS Global Accelerator Zoom Video Conferencing Zoom Adobe Dreamweaver
Similar Organizations
Abalone Bio
Abalone Bio is an early stage biotech start-up that develops antibody drugs for the treatment of diseases.
Acceleron Pharma
Acceleron is a biopharmaceutical company engaged in developing, manufacturing and commercializing novel biotherapeutics.
Ansun BioPharma
Ansun BioPharma is a clinical-stage biopharmaceutical company focused on the development of host-directed anti-viral.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Entrada Therapeutics
Entrada Therapeutics is a developer of novel therapeutics intended to treat devastating diseases.
Imago BioSciences
Imago is a clinical stage biopharmaceutical company discovering new medicines for the treatment of myeloproliferative neoplasms (MPNs).
MBX Biosciences
MBX Biosciences is a preclinical-stage biotech company that creates therapies to treat rare endocrine diseases.
Proteostasis Therapeutics
Proteostasis Therapeutics is a clinical stage biopharmaceutical company developing small molecule therapeutics to treat cystic fibrosis.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
Palisade Bio
Palisade Bio is a clinical-stage biopharmaceutical company developing novel therapies for acute and chronic gastrointestinal complications.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Surrozen
Surrozen is a biopharmaceutical that focuses on unlocking the bodyโs regenerative power to treat injury and disease.
Tiburio Therapeutics
Tiburio Therapeutics is a developer of drug compounds intended to treat tumors and endocrine diseases.
VelosBio
VelosBio is a next-generation oncology company, developing novel antibody-drug conjugates to treat haematological cancers.
Current Advisors List
Current Employees Featured
Founder
Investors List
Rock Springs Capital
Rock Springs Capital investment in Venture Round - ESCAPE Bio
Sutter Hill Ventures
Sutter Hill Ventures investment in Venture Round - ESCAPE Bio
Sphera Funds Management
Sphera Funds Management investment in Venture Round - ESCAPE Bio
Novo Holdings
Novo Holdings investment in Venture Round - ESCAPE Bio
Novartis Venture Fund
Novartis Venture Fund investment in Venture Round - ESCAPE Bio
OrbiMed
OrbiMed investment in Venture Round - ESCAPE Bio
OUP (Osage University Partners)
OUP (Osage University Partners) investment in Venture Round - ESCAPE Bio
Wellington Management
Wellington Management investment in Venture Round - ESCAPE Bio
Johnson & Johnson Innovation โ JJDC
Johnson & Johnson Innovation โ JJDC investment in Venture Round - ESCAPE Bio
New Leaf Ventures
New Leaf Ventures investment in Venture Round - ESCAPE Bio
Official Site Inspections
http://www.escapebio.com Semrush global rank: 9.53 M Semrush visits lastest month: 141
- Host name: 104.21.69.95
- IP address: 104.21.69.95
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ESCAPE Bio"
ESCAPE Bio - Crunchbase Company Profile & Funding
Contact Email [email protected] Phone Number 650-431-0100 Escape Bio is a clinical-stage biopharmaceutical company that develops small molecule โฆSee details»
Escape Bio - Products, Competitors, Financials, Employees, โฆ
Headquarters Location. 4000 Shoreline Court Suite 400. South San Francisco, California, 94080, United States. 650-248-3457See details»
ESCAPE Bio - LinkedIn
ESCAPE Bio | 4,633 followers on LinkedIn. A CLINICAL-STAGE COMPANY DEVELOPING NOVEL, PRECISELY TARGETED THERAPIES FOR GENETIC NEURODEGENERATIVE โฆSee details»
Keluaran SDY
Keluaran SDYSee details»
ESCAPE Bio - Org Chart, Teams, Culture & Jobs - The Org
View ESCAPE Bio's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more.See details»
ESCAPE Bio - Company Profile - Tracxn
Oct 22, 2024 What are the most recent funding rounds of ESCAPE Bio? Its latest funding round was a Series C round on Sep 14, 2020 for $73M. 12 investors participated in its latest round, โฆSee details»
ESCAPE Bio's Leadership Team - Team members and org chart
About. The leadership team at ESCAPE Bio has a lot of experience in the pharmaceutical industry. Many of them have worked at big companies like Genentech, Pfizer, and โฆSee details»
ESCAPE Bio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Sign Up for Free. Last update 01 Nov 2024See details»
ESCAPE Bio - VentureRadar
Website: https://www.escapebio.com/ Develops small molecule therapies for genetically-defined subpopulations in neurodegenerative diseases through a clinical stage ...See details»
ESCAPE Bio Overview | SignalHire Company Profile
[email protected]: Phone Number: 650.431.0100: ESCAPE Bio industries Biotech, Biotechnology: Headquarters Location: 4000 Shoreline Court, Suite 400, South San Francisco, โฆSee details»
'Sorry, Escape Bio closed': A neurodegenerative upstart exits bid to ...
Jan 4, 2023 A neurodegenerative disease-focused biotech that was attempting to go up against the billion-dollar pairing of Biogen and Denali has shuttered, Endpoints News has learned. โฆSee details»
ESCAPE Bio - Company Profile & Staff Directory - ContactOut
ESCAPE Bio is a preclinical stage biopharmaceutical company focused on the discovery and development of therapies to treat genetically defined, neurodegenerative diseases. We are โฆSee details»
ESCAPE Bio, Inc. (ESCAPE Bio, Inc.) - ่ฏ็ฉ็ฎก็บฟ_ไธๅฉ_ไธดๅบ่ฏ้ช_ๆ่ โฆ
The G2019S variant of LRRK2, which causes an increase in kinase activity, is associated with the occurrence of Parkinsons disease (PD).Potent, mutation-selective, and brain penetrant โฆSee details»
ESCAPE Bio - VentureRadar
ESCAPE Bio is passionate about making a meaningful impact on patients suffering from CNS disordersโand where we believe genetics is key to achieving... ... Find out ...See details»
ESCAPE Bio Appoints Edward Owens and Scott Morrison to Board โฆ
Dec 11, 2020 Mr. Morrison has also served as a director on several life sciences industry boards including the Biotechnology Innovation Organization (BIO) ECS board, the Bay Area โฆSee details»
ESCAPE Bio Appoints Paul Wren, Ph.D., Chief Scientific Officer
Mar 19, 2020 ESCAPE Bio, Inc., a clinical-stage company developing novel, precisely-targeted therapeutics for genetically-defined neurodegenerative diseases, todaySee details»
ESCAPE Bio Appoints Mark Kaufmann as CFO and CBO - FirstWord โฆ
Dec 6, 2021 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- ESCAPE Bio, Inc., a clinical-stage company โฆSee details»
ESCAPE Bio Appoints Paul Wren, Ph.D., Chief Scientific Officer
Mar 19, 2020 SAN FRANCISCO--(BUSINESS WIRE)-- ESCAPE Bio, Inc., a clinical-stage company developing novel, precisely-targeted therapeutics for genetically-defined โฆSee details»
ESCAPE Bio Appoints Edward Owens and Scott Morrison to Board โฆ
Dec 11, 2020 Morrison has also served as a director on several life sciences industry boards including the Biotechnology Innovation Organization (BIO) ECS board, the Bay Area โฆSee details»
ESCAPE Bio Closes $73M in Crossover Financing
For additional information, please visit www.escapebio.com. About ESB1609 ESB1609 is a novel, orally administered, brain-penetrant and selective sphingosine-1-phosphate 5 (S1P5) receptor โฆSee details»